Eli Lilly’s (NYSE:LLY) Retevmo treatment is approved
by the Food and Drug Administration for three types of tumors:
non-small cell lung cancer, medullary thyroid cancer and other types of
thyroid cancers.
The FDA calls Retevmo (selpercatinib) “the first
therapy approved specifically for cancer patients with RET gene
alterations,” a mutation that occurs in ~2% of lung cancers and 10%-20%
of papillary thyroid cancers.
Lilly’s drug is part of a trend of treating cancer
based on a patient’s genetics rather than the location in the body
where the disease originated.
Lilly will price the drug at $20,600 for 30 days of treatment, the head of the company’s oncology division tells Reuters.
https://seekingalpha.com/news/3572368-fda-approves-eli-lilly-drug-to-treat-three-types-of-tumors
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.